CLDI Stock Summary and Trading Ideas (Calidi Biotherapeutics | AMEX:CLDI)

Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.

Calidi Biotherapeutics trades on the AMEX stock market under the symbol CLDI.

As of April 10, 2026, CLDI stock price was flat at $0.26 with 432,000 million shares trading.

CLDI has a beta of 1.89, meaning it tends to be more sensitive to market movements. CLDI has a correlation of 0.02 to the broad based SPY ETF.

CLDI has a market cap of $2.44 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that CLDI belongs to (by Net Assets): VXF.

CLDI has underperformed the market in the last year with a price return of -94.8% while the SPY ETF gained +30.9%. CLDI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -77.7% and -5.2%, respectively, while the SPY returned -1.8% and +7.2%, respectively.

CLDI support price is $.24 and resistance is $.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLDI shares will trade within this expected range on the day.